<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01580007</url>
  </required_header>
  <id_info>
    <org_study_id>PR-09068</org_study_id>
    <nct_id>NCT01580007</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)</brief_title>
  <official_title>Clinical Trial of Oral Phenylbutyrate and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis in Bangladesh: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Centre for Diarrhoeal Disease Research, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Tuberculosis Reference Laboratory, National Institute of Diseases of Chest and Hospital (NIDCH), Dhaka, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iceland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International Centre for Diarrhoeal Disease Research, Bangladesh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D exerts its effects via the Vitamin D Receptor (VDR) present in activated
      macrophages and induces expression and release of the cathelicidin, LL-37, a human
      antimicrobial peptide involved in killing of MTB. We aimed to investigate whether treatment
      of newly diagnosed pulmonary TB patients for 2 months with adjunctive PBA and vitamin D
      (Cholecalciferol) in combination with standard DOTS therapy (i) can improve response to
      standard short course TB therapy towards a rapid recovery; (ii) can induce expression of
      LL-37 in macrophages; (iii) can enhance killing capacity of macrophages isolated from TB
      patients infected in vitro with MTB; and (iv) does not evoke any adverse effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, placebo controlled clinical trial on clinical efficacy of
      phenylbutyrate and vitamin D3 therapy daily for 2 months in newly diagnosed sputum smear
      positive pulmonary TB patients. The clinical trial will take place in the National Institute
      of the Diseases of the Chest and Hospital (NIDCH) in Dhaka, Bangladesh.

      Our specific aims are:

      Objective 1: To determine the optimal oral dose of PBA required for induction of
      antimicrobial peptide in macrophages from healthy adults.

      Objective 2

      The second aim of this study is to determine whether adjunctive sodium phenylbutyrate and
      vitamin D treatment (for 2 months) of newly diagnosed pulmonary TB patients:

        1. Can improve response to standard short course TB therapy towards a rapid recovery
           (clinical, radiological, mycobacterial).

        2. Can induce expression of LL-37 in macrophages (immunological).

        3. Can enhance killing capacity of macrophages from TB patients infected in vitro with MTB
           (functional measures of treatment outcome).

      Study Design: The study will be a randomized, double blind (Subject, Caregiver, Investigator,
      Outcomes Assessor), placebo control trial for 2 months. It will also be a safety and efficacy
      phase III study. The study will have a 4x4 factorial design with 4-cell interventions.
      Enrolled patients will be randomized into the following four treatment arms in a 1:1:1:1
      ratio:

      Group 1: PBA Group 2: Vitamin D3 (Cholecalciferol) Group 3: PBA plus vitamin D3 Group 4:
      Placebo
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of pulmonary TB patients who are culture negative in sputum in week 4</measure>
    <time_frame>week 4</time_frame>
    <description>To determine the proportion of sputum culture positive patients becoming culture negative at 1 and 2 months after adjunctive sodium phenylbutyrate and vitamin D treatment of patients for 2 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in improvement in clinical endpoints consisting of cough clearance, percentage chest x-ray clearance, fever remission and weight increase upto 8 weeks.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Difference in improvement in clinical endpoints consisting of:
cough clearance (weekly to week-8 then at week 24) chest x-ray impovement (percentage lung involvement on CXR at week 8) fever remission (weekly to week-8 then at week 24) weight increase (weekly to week-8 then at week 24)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sputum smear conversion time</measure>
    <time_frame>weekly up to week 12; then at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological improvement (percent lung involvement on CXR)</measure>
    <time_frame>week 0, 8, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cough clearance</measure>
    <time_frame>weekly up to week 12; then at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight gain</measure>
    <time_frame>weekly up to week 12, then at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma PBA concentrations</measure>
    <time_frame>week 0, 4, 8, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma 25(OH)D3 concentration</measure>
    <time_frame>week 0, 4, 8, 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical failure and default independently and 'death or clinical failure or default'</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypercalcaemia (serum calcium &gt; 2.6 mmol/L)</measure>
    <time_frame>week 0, 2, 4, 8, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal side effects</measure>
    <time_frame>weekly to week 12 then at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological improvement (LL-37 in macrophages)</measure>
    <time_frame>week 0, 4, 8, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional immunological improvement (killing by macrophages)</measure>
    <time_frame>week 0, 4, 8, 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">288</enrollment>
  <condition>Pulmonary Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Active Sodium Phenylbutyrate and active cholecalciferol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mg sodium phenylbutyrate (4-phenylbutyric acid, sodium salt) in tablet form twice daily and 5000 IU of cholecalciferol once daily will be given orally for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Sodium Phenylbutyrate plus active cholecalciferol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Cholecalciferol Placebo: Sodium Phenylbutyrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Sodium Phenylbutyrate and placebo cholecalciferol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Sodium Phenylbutyrate Placebo: cholecalciferol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Sodium Phenylbutyrate plus placebo cholecalciferol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Sodium Phenylbutyrate Placebo cholecalciferol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Sodium Phenylbutyrate and active cholecalciferol</intervention_name>
    <description>Sodium Phenylbutyrate: 500 mg twice daily orally for 2 months Cholecalciferol: 5000 IU once daily orally for 2 months</description>
    <arm_group_label>Active Sodium Phenylbutyrate and active cholecalciferol</arm_group_label>
    <other_name>triButyrate®</other_name>
    <other_name>Vigantol oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Sodium Phenylbutyrate plus active cholecalciferol</intervention_name>
    <description>Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Cholecalciferol: 5000 IU once daily for 2 months</description>
    <arm_group_label>Placebo Sodium Phenylbutyrate plus active cholecalciferol</arm_group_label>
    <other_name>Vigantol oil</other_name>
    <other_name>Placebo Phenylbutyrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Sodium Phenylbutyrate and placebo cholecalciferol</intervention_name>
    <description>Sodium phenylbutyrate: 500 mg twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months</description>
    <arm_group_label>Active Sodium Phenylbutyrate and placebo cholecalciferol</arm_group_label>
    <other_name>triButyrate®</other_name>
    <other_name>Placebo vigantol oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Sodium Phenylbutyrate plus placebo cholecalciferol</intervention_name>
    <description>Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months</description>
    <arm_group_label>Placebo Sodium Phenylbutyrate plus placebo cholecalciferol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults, 18-60 years with sputum smear positive pulmonary TB

          -  New cases only

          -  Gender, both

          -  Consent to enroll in the study

        Exclusion Criteria:

          -  Hypercalcaemia (serum calcium &gt; 2.6 mmol/L) identified at baseline

          -  Taking vitamin D

          -  Pregnant and lactating

          -  Any known liver or kidney function abnormality, malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institute of Diseases of Chest and Hospital (NIDCH)</name>
      <address>
        <city>Dhaka</city>
        <zip>1212</zip>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2012</study_first_submitted>
  <study_first_submitted_qc>April 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2012</study_first_posted>
  <last_update_submitted>February 12, 2015</last_update_submitted>
  <last_update_submitted_qc>February 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tuberculosis</keyword>
  <keyword>phenylbutyrate</keyword>
  <keyword>vitamin D</keyword>
  <keyword>cathelicidin</keyword>
  <keyword>antimicrobial peptide</keyword>
  <keyword>in adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>4-phenylbutyric acid</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 3, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

